PMID- 12208316
OWN - NLM
STAT- MEDLINE
DCOM- 20030310
LR  - 20190624
IS  - 0014-2999 (Print)
IS  - 0014-2999 (Linking)
VI  - 450
IP  - 3
DP  - 2002 Aug 30
TI  - Preprotachykinin A gene expression after administration of 3,4-methylene 
      dioxymethamphetamine (Ecstasy).
PG  - 245-51
AB  - This study tested the effects of 8 days of subchronic administration of 
      3,4-methylene dioxymethamphetamine (MDMA) (5 mg/kg b.w.) on preprotachykinin A 
      mRNA levels in discrete rat brain regions. In situ hybridization examined 
      preprotachykinin A mRNA levels in the core and shell of the nucleus accumbens, 
      the islands of Calleja, the olfactory tubercle, the dorsal and ventral 
      caudate-putamen, the bed nucleus of the stria terminalis, the medial preoptic 
      area, the medial habenular nucleus and in the postero-dorsal part of the medial 
      amygdala. Higher levels of preprotachykinin A mRNA were found in the core and 
      shell of the nucleus accumbens, in the islands of calleja, in the olfactory 
      tubercle, in the bed nucleus of the stria terminalis, in the medial habenular 
      nucleus and the postero-dorsal part of the medial amygdala, compared to control 
      animals. Conversely, increased preprotachykinin A mRNA levels were observed in 
      the dorsal and ventral caudate-putamen in MDMA treated when compared to control 
      rats. In the social memory test, MDMA significantly impaired rats' short-term 
      working memory. These results show that chronic exposure to MDMA strongly affects 
      preprotachykinin A mRNA levels in discrete rat brain regions. These changes occur 
      in experimental conditions in which working memory is markedly reduced, 
      suggesting that changes in gene expression of tachykinin mechanisms may 
      contribute to the effects of MDMA on memory function.
FAU - Pompei, Pierluigi
AU  - Pompei P
AD  - Department of Pharmacological Sciences and Experimental Medicine, University of 
      Camerino, Via Scalzino 3, 62032 Camerino (MC), Italy. pete.pompei@unicam.it
FAU - Cavazzuti, Elena
AU  - Cavazzuti E
FAU - Martarelli, Daniele
AU  - Martarelli D
FAU - Pediconi, Dario
AU  - Pediconi D
FAU - Arletti, Rossana
AU  - Arletti R
FAU - Lucas, Louis
AU  - Lucas L
FAU - Massi, Maurizio
AU  - Massi M
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - Netherlands
TA  - Eur J Pharmacol
JT  - European journal of pharmacology
JID - 1254354
RN  - 0 (Hallucinogens)
RN  - 0 (Protein Precursors)
RN  - 0 (RNA, Messenger)
RN  - 0 (Tachykinins)
RN  - 0 (preprotachykinin)
RN  - KE1SEN21RM (N-Methyl-3,4-methylenedioxyamphetamine)
SB  - IM
MH  - Animals
MH  - Brain/metabolism
MH  - Gene Expression
MH  - Hallucinogens/administration & dosage/*pharmacology
MH  - Injections, Intraperitoneal
MH  - Male
MH  - Memory/drug effects
MH  - N-Methyl-3,4-methylenedioxyamphetamine/administration & dosage/*pharmacology
MH  - Protein Precursors/*biosynthesis/genetics
MH  - RNA, Messenger/biosynthesis
MH  - Rats
MH  - Rats, Sprague-Dawley
MH  - Tachykinins/*biosynthesis/genetics
EDAT- 2002/09/05 10:00
MHDA- 2003/03/11 04:00
CRDT- 2002/09/05 10:00
PHST- 2002/09/05 10:00 [pubmed]
PHST- 2003/03/11 04:00 [medline]
PHST- 2002/09/05 10:00 [entrez]
AID - S0014299902021581 [pii]
AID - 10.1016/s0014-2999(02)02158-1 [doi]
PST - ppublish
SO  - Eur J Pharmacol. 2002 Aug 30;450(3):245-51. doi: 10.1016/s0014-2999(02)02158-1.